Psoriasis biologics comparison
DermatologyCompare biologic therapies for moderate-to-severe plaque psoriasis. Modern IL-17 and IL-23 inhibitors offer high skin clearance rates. Choice depends on insurance formulary position, mechanism preference, and dosing convenience.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Skyrizi | AbbVie | SC injection | Every 12 weeks (after loading) | IL-23 inhibitor; highest PASI 90/100 rates; extended dosing interval |
| Tremfya | Janssen | SC injection | Every 8 weeks (after loading) | IL-23 inhibitor; also approved for PsA |
| Cosentyx | Novartis | SC injection | Every 4 weeks (after loading) | IL-17A inhibitor; approved for psoriasis, PsA, and AS |
| Taltz | Eli Lilly | SC injection | Every 4 weeks (after loading) | IL-17A inhibitor; rapid onset of action |
| Stelara | Janssen | SC injection | Every 12 weeks (after loading) | IL-12/23 inhibitor; long track record; biosimilars available |
| Humira | AbbVie | SC injection | Every 2 weeks | TNF inhibitor; biosimilars widely available; more frequent dosing |
| Sotyktu | BMS | Oral (tablet) | Daily | Oral TYK2 inhibitor; no injection required; newer agent |
| Otezla | Amgen | Oral (tablet) | Twice daily | Oral PDE4 inhibitor; no immunosuppression; lower efficacy than biologics |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.